AP200001795A0 - Substituted 4-aminothiazol-2-yol - Google Patents

Substituted 4-aminothiazol-2-yol

Info

Publication number
AP200001795A0
AP200001795A0 AP200001795A AP200001795A AP200001795A0 AP 200001795 A0 AP200001795 A0 AP 200001795A0 AP 200001795 A AP200001795 A AP 200001795A AP 200001795 A AP200001795 A AP 200001795A AP 200001795 A0 AP200001795 A0 AP 200001795A0
Authority
AP
ARIPO
Prior art keywords
yol
aminothiazol
substituted
Prior art date
Application number
AP200001795A
Other versions
AP1445A (en
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US6363497P priority Critical
Priority to US6366697P priority
Application filed by Agouron Pharma filed Critical Agouron Pharma
Priority to PCT/US1998/022809 priority patent/WO1999021845A2/en
Publication of AP200001795A0 publication Critical patent/AP200001795A0/en
Application granted granted Critical
Publication of AP1445A publication Critical patent/AP1445A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
APAP/P/2000/001795A 1997-10-27 1998-10-27 Substituted 4-amino-thiazol-2-yl compounds as CDKs inhibitors. AP1445A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US6363497P true 1997-10-27 1997-10-27
US6366697P true 1997-10-28 1997-10-28
PCT/US1998/022809 WO1999021845A2 (en) 1997-10-27 1998-10-27 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

Publications (2)

Publication Number Publication Date
AP200001795A0 true AP200001795A0 (en) 2000-06-30
AP1445A AP1445A (en) 2005-07-10

Family

ID=26743609

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001795A AP1445A (en) 1997-10-27 1998-10-27 Substituted 4-amino-thiazol-2-yl compounds as CDKs inhibitors.

Country Status (33)

Country Link
US (2) US6569878B1 (en)
EP (1) EP1056732B1 (en)
JP (1) JP2004500304A (en)
KR (1) KR20010082501A (en)
CN (1) CN1158269C (en)
AP (1) AP1445A (en)
AT (2) AT315553T (en)
AU (1) AU738792B2 (en)
BG (1) BG64195B1 (en)
BR (1) BR9815200A (en)
CA (1) CA2306082A1 (en)
DE (2) DE69835241T2 (en)
EA (1) EA003527B1 (en)
EE (1) EE200000289A (en)
ES (2) ES2256968T3 (en)
GE (1) GEP20032896B (en)
HR (1) HRP20000222A2 (en)
HU (1) HU0004512A3 (en)
ID (1) ID24372A (en)
IL (1) IL135574D0 (en)
IS (1) IS5462A (en)
LT (1) LT4855B (en)
LV (1) LV12592B (en)
NO (1) NO20001955L (en)
NZ (1) NZ503788A (en)
OA (1) OA11352A (en)
PL (1) PL342447A1 (en)
RO (1) RO119463B1 (en)
SI (1) SI20324A (en)
SK (1) SK5212000A3 (en)
TR (1) TR200001081T2 (en)
WO (1) WO1999021845A2 (en)
YU (1) YU22400A (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69835241T2 (en) * 1997-10-27 2007-05-31 Agouron Pharmaceuticals, Inc., La Jolla 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
ID27006A (en) 1998-06-04 2001-02-22 Pfizer Prod Inc Isotiazol derivatives useful as anti-cancer agent
CN1129581C (en) * 1998-09-22 2003-12-03 山之内制药株式会社 Cyanophenyl derivatives
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP3989175B2 (en) 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Cyclic protein tyrosine kinase inhibitor
CZ20014213A3 (en) * 1999-06-04 2002-04-17 Agouron Pharmaceuticals, Inc. Diaminothiazoles and their use for inhibition of protein kinases
PE20010306A1 (en) * 1999-07-02 2001-03-29 Agouron Pharma Indazole compounds and pharmaceutical compositions containing them useful for the inhibition of protein kinase
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
YU54202A (en) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
HN2001000008A (en) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals And amide compound to inhibit protein kinases pharmaceutical compositions and method of use
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
KR100423899B1 (en) 2000-05-10 2004-03-24 주식회사 엘지생명과학 Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
JP2004505983A (en) * 2000-08-09 2004-02-26 アグーロン ファーマシューティカルズ,インコーポレイテッド Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods for their use for inhibition of cyclin dependent kinases
DE60110802T2 (en) 2000-08-18 2005-10-06 Agouron Pharmaceuticals, Inc., San Diego Heterocyclic hydroximino fluorene and its use in the inhibition of protein kinases
EP1712550A3 (en) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
PL363316A1 (en) 2000-12-22 2004-11-15 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
JP2004535437A (en) * 2001-06-22 2004-11-25 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Tyrosine kinase inhibitor
HN2002000156A (en) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Benzamide thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for use.
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
JP2004538315A (en) * 2001-08-03 2004-12-24 ノボ・ノルデイスク・エー/エス New 2,4-diaminothiazole derivatives
CN101001857B (en) 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
US6818663B2 (en) * 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
EP1515975B1 (en) 2002-06-14 2007-09-19 Pfizer Inc. Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
BR0312798A (en) 2002-07-25 2005-05-03 Pfizer Prod Inc Isothiazole derivatives useful as anticancer agents
EP1539722A1 (en) 2002-08-07 2005-06-15 F. Hoffmann-La Roche Ag Thiazole derivatives
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
WO2004072070A1 (en) * 2003-02-12 2004-08-26 Pfizer Inc. Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives
BRPI0407618A (en) * 2003-02-21 2006-02-21 Pfizer cycloalkyl-substituted amino thiazole derivatives containing n and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
BRPI0410905A (en) 2003-06-03 2006-06-27 Novartis Ag p-38 inhibitors
ES2393950T3 (en) 2003-06-26 2013-01-02 Novartis Ag P38 kinase inhibitors based on 5-membered heterocycles
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
PT1651615E (en) 2003-07-29 2010-04-29 High Point Pharmaceuticals Llc Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
US20070275918A1 (en) * 2003-11-07 2007-11-29 The Board Of Trustees Of The University Of Illinois Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
JP2007513967A (en) * 2003-12-11 2007-05-31 セラヴァンス, インコーポレーテッド Compositions for use in the treatment of cell proliferative diseases driven by mutant receptor tyrosine kinases
EP1550372A1 (en) * 2003-12-24 2005-07-06 Bayer CropScience GmbH Plant growth regulation
EP1711497A1 (en) * 2004-01-30 2006-10-18 AB Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
AU2005230846A1 (en) * 2004-03-31 2005-10-20 Lexicon Pharmaceuticals, Inc. 2-aminomethylthiazole-5-carboxamides as protein kinase modulators
US7211576B2 (en) * 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423051B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US7423053B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
CA2583428A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
US7241893B2 (en) * 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
KR100875870B1 (en) 2004-10-14 2008-12-26 에프. 호프만-라 로슈 아게 Novel azaindole thiazolinones as anticancer agents
JP2008526721A (en) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of CDK, GSK and Aurora kinase
KR101334511B1 (en) 2004-12-30 2013-11-29 아스텍스 테라퓨틱스 리미티드 Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
BRPI0606480A (en) 2005-01-21 2008-03-11 Astex Therapeutics Ltd Pharmaceutical compounds
MX2007008781A (en) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Pharmaceutical compounds.
US7304074B2 (en) 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
ES2375929T3 (en) 2005-07-04 2012-03-07 High Point Pharmaceuticals, Llc Histamine receiver antagonists h3.
EP2301928A1 (en) 2005-07-30 2011-03-30 AstraZeneca AB Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
KR101280333B1 (en) 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 Benzothiazoles having histamine h3 receptor activity
CA2653062A1 (en) 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
JP5568312B2 (en) * 2007-02-13 2014-08-06 アーべー・シオンス Method for synthesizing 2-aminothiazole compounds as kinase inhibitors
RU2009140182A (en) * 2007-05-11 2011-06-20 Ф. Хоффманн-Ля Рош Аг (Ch) Hetarilanilines as modulators for beta amyloid
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
SG11201404596UA (en) * 2012-02-02 2014-10-30 Senex Biotechnology Inc Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
CN102977049A (en) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 Method for synthesizing 2-amino-4-cyclopropyl-5-carboxylate thiazole
SG11201509194SA (en) 2013-05-07 2015-12-30 Univ California Radiomitigating pharmaceutical formulations
CN104628627A (en) * 2014-12-23 2015-05-20 安徽德信佳生物医药有限公司 Method for synthesizing 1-boc-4-aminopiperidine
CN106854200B (en) * 2015-12-08 2019-05-21 上海复星星泰医药科技有限公司 The preparation method of Ceritinib and its intermediate
WO2018089902A1 (en) * 2016-11-13 2018-05-17 Apogee Biotechnology Corporation Diaminothiazole compounds, compositions and methods of use
WO2018124001A1 (en) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmp-signal-inhibiting compound

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3530161A (en) 1968-08-19 1970-09-22 Shell Oil Co Aromatic isothiocyanate production
BE792402A (en) 1971-12-07 1973-06-07 Ciba Geigy Nitrogen heterocyclic compounds and drugs which contain antimicrobial anthelminthiqueset
CH593806A5 (en) 1974-11-14 1977-12-15 Ciba Geigy Ag
US4086239A (en) 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
DE3804531A1 (en) 1988-02-13 1989-08-24 Bayer Ag 5-cyano-2,4-diamino-thiazole derivatives
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
US5620963A (en) 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
WO1992020642A1 (en) * 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH07502164A (en) 1991-09-20 1995-03-09
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5441880A (en) 1991-11-18 1995-08-15 Cold Spring Harbor Laboratory Human cdc25 genes, encoded products and uses thereof
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
DE69334053T2 (en) 1992-04-10 2007-01-04 Dana-Farber Cancer Institute, Inc., Boston Immuno protection of an active state-specific phosphoprotein
AU5168393A (en) 1992-09-30 1994-04-26 Yale University Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
US5543291A (en) 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
WO1994026303A1 (en) 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5514571A (en) 1993-08-05 1996-05-07 University Technologies International Inc. Cyclin D1 negative regulatory activity
US5473056A (en) 1993-10-13 1995-12-05 Merck & Co., Inc. E2F-2, a novel mammalian transcription factor
US5532167A (en) 1994-01-07 1996-07-02 Beth Israel Hospital Substrate specificity of protein kinases
US5484710A (en) 1994-01-14 1996-01-16 La Jolla Cancer Research Foundation Method of down-regulating a gene linked to a P-53 responsive element
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0702730A4 (en) 1994-03-18 1997-05-07 Univ Utah Res Found Germline mutations in the mts gene and method for detecting predisposition to cancer at the mts gene
US5496831A (en) 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
CN1066147C (en) 1995-11-01 2001-05-23 诺瓦提斯公司 Purine derivatives and processes for their preparation
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
DZ2285A1 (en) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibitors of cysteine ​​protease.
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
DE69839338T2 (en) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine and 4-amino-pyrimidine as inhibitors of cellular proliferation
DE69835241T2 (en) * 1997-10-27 2007-05-31 Agouron Pharmaceuticals, Inc., La Jolla 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
CZ20014213A3 (en) * 1999-06-04 2002-04-17 Agouron Pharmaceuticals, Inc. Diaminothiazoles and their use for inhibition of protein kinases

Also Published As

Publication number Publication date
BR9815200A (en) 2001-10-16
DE69835241D1 (en) 2006-08-24
AP1445A (en) 2005-07-10
ES2256968T3 (en) 2006-07-16
EA200000464A1 (en) 2000-12-25
SI20324A (en) 2001-02-28
BG64195B1 (en) 2004-04-30
TR200001081T2 (en) 2000-10-23
NO20001955D0 (en) 2000-04-14
ID24372A (en) 2000-07-13
EP1056732A2 (en) 2000-12-06
EA003527B1 (en) 2003-06-26
WO1999021845A2 (en) 1999-05-06
GEP20032896B (en) 2002-09-10
EE200000289A (en) 2001-06-15
IL135574D0 (en) 2001-05-20
DE69833223D1 (en) 2006-04-06
WO1999021845A3 (en) 1999-08-19
IS5462A (en) 2000-04-19
US6569878B1 (en) 2003-05-27
EP1056732B1 (en) 2006-01-11
HRP20000222A2 (en) 2001-02-28
YU22400A (en) 2003-08-29
RO119463B1 (en) 2004-11-30
CA2306082A1 (en) 1999-05-06
CN1158269C (en) 2004-07-21
AT332896T (en) 2006-08-15
AT315553T (en) 2006-02-15
NZ503788A (en) 2002-11-26
OA11352A (en) 2003-12-23
HU0004512A2 (en) 2002-03-28
LT2000033A (en) 2001-06-25
ES2267873T3 (en) 2007-03-16
LT4855B (en) 2001-11-26
AU738792B2 (en) 2001-09-27
BG104478A (en) 2001-02-28
LV12592A (en) 2000-12-20
PL342447A1 (en) 2001-06-04
HU0004512A3 (en) 2003-01-28
SK5212000A3 (en) 2001-04-09
LV12592B (en) 2001-07-20
NO20001955L (en) 2000-06-16
DE69835241T2 (en) 2007-05-31
US20030220326A1 (en) 2003-11-27
KR20010082501A (en) 2001-08-30
JP2004500304A (en) 2004-01-08
AU1366499A (en) 1999-05-17
DE69833223T2 (en) 2006-09-14
CN1276789A (en) 2000-12-13

Similar Documents

Publication Publication Date Title
DE69810130D1 (en) Rotationspumpe mit tauchrotor
DE69817801D1 (en) Arylsulfonylhydroxamsäurederivate
DE69826273D1 (en) Knochentransplantat-composite und -spacern
DE69800640D1 (en) Pegylationsverfahren
DE69826254D1 (en) Modulare humerusprothese
DE69807872D1 (en) Thermoplastisches polyetherurethan
DE69817191D1 (en) Roboter-mäher
DE69837675D1 (en) Pyrazolderivate
DE69821950D1 (en) N-aroylphenylalaninderivate
DE69709184D1 (en) Knöchel-fuss orthese
DE69804946D1 (en) Opthalmische formmasse
DE69831868D1 (en) Antithrombosemittel
DE69808438D1 (en) Hüftprothese
DE69827612D1 (en) Meatuspfropf
DE69840963D1 (en) Thermale therapievorrichtung
IL135248D0 (en) Novel combination
DE69809754D1 (en) Substituierte 6-phenylphenanthridine
ZA9810249B (en) Novel substituted phenylketoenols
DE69835201D1 (en) Neoglycoproteine
GB9825535D0 (en) Pyrometer-multimeter
DE69816992D1 (en) Benzimidazolderivate
HU9800208D0 (en) Omega-cycloalkyl-prostaglandin e2-derivatives
PL189418B1 (en) Novel phtalysinones
DE69829667D1 (en) Hydrocyanierungsverfahren
DE69838100D1 (en) Gefässprothese